Health economics and outcomes research (HEOR) experts at the USC-Brookings Schaeffer Initiative for Health Policy and the Washington University School of Law reveal a framework intended to guide discussions and policy on drug pricing reform. Their comprehensive framework details Medicare Part D expansion, the Food and Drug Administration’s accelerated approval mechanism, pricing negotiation, and repurposing existing drugs.
The authors remark, “In this post, we present a framework for categorizing and analyzing a wide range of proposed policy reforms for prescription drug pricing. We argue that policymakers should think about reform options as fitting within three sets of categories: (1) those focusing on patients’ out-of-pocket costs; (2) those targeting problematic incentives for various stakeholders within the system; and (3) those addressing the high prices of particular drugs.” Read more here.
(Source: Rachel Sachs, Loren Adler, and Paul Ginsburg, USC-Brookings Schaeffer Initiative for Health Policy, 8/31/21)